PE20010739A1 - Combinacion de nateglinida y un compuesto antidiabetico para el tratamiento de desordenes metabolicos, especialmente diabetes, o una enfermedad o condicion asociada con diabetes - Google Patents
Combinacion de nateglinida y un compuesto antidiabetico para el tratamiento de desordenes metabolicos, especialmente diabetes, o una enfermedad o condicion asociada con diabetesInfo
- Publication number
- PE20010739A1 PE20010739A1 PE2000000955A PE0009552000A PE20010739A1 PE 20010739 A1 PE20010739 A1 PE 20010739A1 PE 2000000955 A PE2000000955 A PE 2000000955A PE 0009552000 A PE0009552000 A PE 0009552000A PE 20010739 A1 PE20010739 A1 PE 20010739A1
- Authority
- PE
- Peru
- Prior art keywords
- nateglinide
- diabetes
- treatment
- combination
- composition
- Prior art date
Links
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title abstract 4
- 229960000698 nateglinide Drugs 0.000 title abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229960004586 rosiglitazone Drugs 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001641 troglitazone Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMBINACION QUE COMPRENDE: a)NATEGLINIDA DE FORMULA I PRESENTE EN LA MODIFICACION DEL CRISTAL TIPO B O TIPO H; b)UN COMPUESTO ANTIDIABETICO COMO: i)TIAZOLIDINDIONA COMO GLITAZONAS (ROSIGLITAZONA, TROGLITAZONA, PIOGLITAZONA), ii)DERIVADOS DE SULFONILUREA, iii)METFORMINA; c)INSULINA; d)UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION FARMACEUTICA ESTA EN FORMA DE TABLETA, GRANULO, CAPSULA; Y SE PUEDE GRANULAR EN PRESENCIA DE 25% A 80% PESO DE AGUA, SIN NECESIDAD DE UNA PULVERIZACION SUBSECUENTE PARA FORMAR UNA COMPOSICION CON APROXIMADAMENTE 20% EN PESO DE GRANULOS CON UN TAMANO DE 250 MICRAS O MAS. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE NATEGLINIDA; UN DESINTEGRANTE TAL COMO POLIVINILPIRROLIDONA RETICULADA CON UN PESO MOLECULAR MAYOR A 1,000,000, CON UNA DISTRIBUCION MENOR A 400 MICRAS O 74 MICRAS CARACTERIZADO PORQUE SE LIBERA EL 60% A 95% DE NATEGLINIDA DENTRO DE UN PERIODO DE 30 MINUTOS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE DESORDENES METABOLICOS COMO DIABETES, PERDIDA DE PESO
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39836499A | 1999-09-17 | 1999-09-17 | |
| US54548000A | 2000-04-07 | 2000-04-07 | |
| GB0021055A GB0021055D0 (en) | 2000-08-26 | 2000-08-26 | Method of treating metabolic disorders,espicially diabetes,or a disease or condition associated with diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010739A1 true PE20010739A1 (es) | 2001-07-13 |
Family
ID=27255861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000955A PE20010739A1 (es) | 1999-09-17 | 2000-09-15 | Combinacion de nateglinida y un compuesto antidiabetico para el tratamiento de desordenes metabolicos, especialmente diabetes, o una enfermedad o condicion asociada con diabetes |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1212077A2 (es) |
| JP (2) | JP2003509457A (es) |
| KR (2) | KR100544244B1 (es) |
| CN (1) | CN1309380C (es) |
| AR (3) | AR028299A1 (es) |
| AU (1) | AU7904400A (es) |
| BE (1) | BE1013726A5 (es) |
| BR (1) | BR0014525A (es) |
| CA (1) | CA2381992C (es) |
| CO (1) | CO5200844A1 (es) |
| CZ (1) | CZ20011723A3 (es) |
| FI (1) | FI20010683A (es) |
| FR (1) | FR2798592B1 (es) |
| HK (1) | HK1046101A1 (es) |
| HU (1) | HUP0400932A3 (es) |
| IL (1) | IL148168A0 (es) |
| MY (2) | MY131810A (es) |
| NO (1) | NO20021197L (es) |
| NZ (2) | NZ528738A (es) |
| PE (1) | PE20010739A1 (es) |
| PL (1) | PL354168A1 (es) |
| SG (1) | SG127714A1 (es) |
| SK (1) | SK3602002A3 (es) |
| TW (2) | TWI278311B (es) |
| WO (1) | WO2001021159A2 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| ATE310507T1 (de) | 1999-12-28 | 2005-12-15 | Ajinomoto Kk | Orale zusammensetzungen für diabetes |
| SK14922002A3 (sk) * | 2000-03-17 | 2003-04-01 | Ajinomoto Co., Inc. | Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru |
| FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
| FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP1385549A2 (en) * | 2001-03-12 | 2004-02-04 | Novartis AG | Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| FR2826278B1 (fr) * | 2001-06-20 | 2005-03-25 | Lipha | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
| DK1397124T3 (da) * | 2001-06-20 | 2007-04-02 | Merck Sante Sas | Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning |
| EP1483232A1 (en) * | 2002-03-11 | 2004-12-08 | Novartis AG | Salts of nateglinide |
| WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
| AU2003241823A1 (en) * | 2002-05-28 | 2003-12-12 | Ajinomoto Co., Inc. | Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof |
| US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| KR20080083071A (ko) * | 2003-08-08 | 2008-09-12 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| JP5168712B2 (ja) * | 2004-04-01 | 2013-03-27 | 味の素株式会社 | ナテグリニド含有製剤 |
| CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| KR20070040389A (ko) * | 2004-08-10 | 2007-04-16 | 아지노모토 가부시키가이샤 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
| JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 |
| WO2007111933A2 (en) * | 2006-03-22 | 2007-10-04 | Intranasal Therapeutics , Inc. | Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same |
| WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US20100129311A1 (en) * | 2008-11-21 | 2010-05-27 | Auspex Pharmaceuticals, Inc. | Phenylalanine amide inhibitors of atp-sensitive potassium channels |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| KR101035574B1 (ko) * | 2009-04-09 | 2011-05-23 | 대한민국 | 제 2형 당뇨병 치료효과를 판정하는 방법 |
| TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| WO2013103384A1 (en) | 2012-01-06 | 2013-07-11 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| HUE051738T2 (hu) | 2011-01-07 | 2021-03-29 | Anji Pharma Us Llc | Kemoszenzoros receptorligandum-alapú terápiák |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| WO2013066277A1 (en) * | 2011-11-03 | 2013-05-10 | Mahmut Bilgic | Synergic compositions |
| WO2013077820A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Treatment package composed of dosage forms comprising nateglinide -metformin hydrochloride |
| BR112014016810A8 (pt) | 2012-01-06 | 2017-07-04 | Elcelyx Therapeutics Inc | composições e métodos para tratamento de distúrbios metabólicos |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CN105646332B (zh) * | 2014-11-09 | 2018-05-25 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
| CN114099520A (zh) * | 2021-12-31 | 2022-03-01 | 中国药科大学 | 格列喹酮用于制备治疗溃疡性结肠炎的药物的用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
| JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
| JPS55129220A (en) * | 1980-02-08 | 1980-10-06 | Yamanouchi Pharmaceut Co Ltd | Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability |
| JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| US5216167A (en) | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US4635627A (en) | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
| US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| HU210339B (en) | 1985-05-21 | 1995-03-28 | Pfizer | Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect |
| US4806359A (en) * | 1987-04-22 | 1989-02-21 | Mcneilab, Inc. | Iburprofen sustained release matrix and process |
| SG59988A1 (en) | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
| US4997948A (en) | 1989-10-27 | 1991-03-05 | American Home Products | 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
| DE10199058I2 (de) | 1991-07-30 | 2006-04-27 | Alcm Co | Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
| JPH0776516A (ja) * | 1993-09-06 | 1995-03-20 | Toyobo Co Ltd | 難溶性薬物含有製剤の製造方法 |
| JPH07126154A (ja) * | 1993-10-29 | 1995-05-16 | Terumo Corp | 難水溶性医薬品含有医薬製剤 |
| US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| JP4010377B2 (ja) | 1996-09-06 | 2007-11-21 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| PT965339E (pt) * | 1996-11-15 | 2006-06-30 | Ajinomoto Kk | Composicao de nateglinida em comprimidos |
| DK1011673T3 (da) * | 1997-06-13 | 2001-07-09 | Novo Nordisk As | Hidtil ukendt metode til behandling af nidom |
-
2000
- 2000-09-14 AR ARP000104821A patent/AR028299A1/es not_active Application Discontinuation
- 2000-09-14 CO CO00069666A patent/CO5200844A1/es not_active Application Discontinuation
- 2000-09-15 WO PCT/EP2000/009074 patent/WO2001021159A2/en active IP Right Grant
- 2000-09-15 KR KR1020047010952A patent/KR100544244B1/ko not_active IP Right Cessation
- 2000-09-15 PE PE2000000955A patent/PE20010739A1/es not_active Application Discontinuation
- 2000-09-15 IL IL14816800A patent/IL148168A0/xx unknown
- 2000-09-15 HU HU0400932A patent/HUP0400932A3/hu unknown
- 2000-09-15 CN CNB008019762A patent/CN1309380C/zh not_active Expired - Lifetime
- 2000-09-15 JP JP2001524585A patent/JP2003509457A/ja not_active Withdrawn
- 2000-09-15 BE BE2000/0585A patent/BE1013726A5/fr not_active IP Right Cessation
- 2000-09-15 CZ CZ20011723A patent/CZ20011723A3/cs unknown
- 2000-09-15 BR BR0014525-4A patent/BR0014525A/pt not_active IP Right Cessation
- 2000-09-15 TW TW089118960A patent/TWI278311B/zh not_active IP Right Cessation
- 2000-09-15 PL PL00354168A patent/PL354168A1/xx not_active Application Discontinuation
- 2000-09-15 CA CA2381992A patent/CA2381992C/en not_active Expired - Fee Related
- 2000-09-15 NZ NZ528738A patent/NZ528738A/en not_active IP Right Cessation
- 2000-09-15 SK SK360-2002A patent/SK3602002A3/sk unknown
- 2000-09-15 SG SG200401291A patent/SG127714A1/en unknown
- 2000-09-15 AU AU79044/00A patent/AU7904400A/en not_active Abandoned
- 2000-09-15 MY MYPI20004314A patent/MY131810A/en unknown
- 2000-09-15 FR FR0011782A patent/FR2798592B1/fr not_active Expired - Fee Related
- 2000-09-15 KR KR10-2002-7003551A patent/KR100506428B1/ko not_active IP Right Cessation
- 2000-09-15 EP EP00969260A patent/EP1212077A2/en not_active Ceased
- 2000-09-15 EP EP08167253A patent/EP2011507A2/en not_active Withdrawn
- 2000-09-15 NZ NZ517280A patent/NZ517280A/en not_active IP Right Cessation
- 2000-09-15 MY MYPI20050152A patent/MY143051A/en unknown
- 2000-09-15 TW TW092125226A patent/TWI278312B/zh not_active IP Right Cessation
-
2001
- 2001-02-05 AR ARP010100516A patent/AR028504A2/es unknown
- 2001-04-02 FI FI20010683A patent/FI20010683A/fi not_active Application Discontinuation
-
2002
- 2002-03-11 NO NO20021197A patent/NO20021197L/no unknown
- 2002-10-25 HK HK02107767.4A patent/HK1046101A1/zh unknown
-
2006
- 2006-09-06 JP JP2006241423A patent/JP2006335767A/ja active Pending
-
2009
- 2009-07-28 AR ARP090102868A patent/AR072329A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010739A1 (es) | Combinacion de nateglinida y un compuesto antidiabetico para el tratamiento de desordenes metabolicos, especialmente diabetes, o una enfermedad o condicion asociada con diabetes | |
| ES2251195T3 (es) | Acido lipoico de liberacion lenta. | |
| US7897572B1 (en) | Theraputic methods for type I diabetes | |
| ES2611314T3 (es) | Composiciones y procedimientos para usar (R)-pramipexol | |
| TWI481588B (zh) | ５，６-二氫-１ｈ-吡啶-２-酮化合物 | |
| US20090136472A1 (en) | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| UY24861A1 (es) | Derivados de sulfonilurea | |
| JP2006335767A5 (es) | ||
| PL304389A1 (en) | Pharmaceutical composition for controllable release | |
| ES2077897T3 (es) | Preparados farmaceuticos secos de dosis bajas. | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| EP3452018A2 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| RU2005115955A (ru) | Водорастворимые содержащие мелоксикам грануляты | |
| ES2397558T3 (es) | Composición farmacéutica que comprende aleglitazar | |
| PE20030323A1 (es) | Composicion farmaceutica | |
| Rachelefsky | Childhood asthma and allergic rhinitis: the role of leukotrienes | |
| AR025879A1 (es) | Granulaciones de celulosa hidrolizada de sales de farmacos | |
| WO2012113894A1 (en) | Pharmaceutical combination of betahistine and trimetazidine | |
| ATE148340T1 (de) | Naproxen-tabletten mit gesteuerter wirkstoffabgabe | |
| US20090176762A1 (en) | JNK Inhibitors for Treatment of Skin Diseases | |
| WO2021262116A1 (en) | A film coated tablet comprising vildagliptin and metformin hci | |
| RU2002109234A (ru) | Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом | |
| Smith et al. | Effects of acute and chronic administration of phencyclidine on tyrosine hydroxylase activity in rat striatum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |